July 6, 2022

2 Minutes

Cereno Scientific (XSAT:CRNO B) reports first patient enrolled in Phase II study in PAH with drug candidate CS1 and update timeline for top-line results to Q1 2023

Cereno Scientific (XSAT: CRNO B) today reported that the first patient has been enrolled in the Phase II study in pulmonary arterial hypertension (PAH) with drug candidate CS1. Based on the timing of enrollment...
Read More